Eight Emerging U.S. Medical Cost & Access Drivers to Watch in 2026
The U.S. healthcare system never really sits still but 2026 is shaping up to be a year where cost, access, and innovation intersect in new and sometimes uncomfortable ways. From the Inflation Reduction Act’s pricing negotiations to the quiet but powerful spread of value-based models, the rules that govern how therapies reach patients are being rewritten. Below are eight themes we believe will define the next phase of U.S. market access and each carrying very real implications for patients, payers, providers and drug/biotech innovators. 1. Medicare price negotiations move from theory to practice The Inflation Reduction Act (IRA) has already changed boardroom conversations around pricing and lifecycle management, but in 2026 the negotiated prices will finally start taking effect. Manufacturers will face tighter margins on some of their most commercially critical assets. For patients, this could mean lower out-of-pocket costs on selected drugs, but also narrower formularies or ste...